About the Company
Medtronic plc is an American medical device company. The companys operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MDT News
Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug ...
Medtronic's Latest Generation Of Transcatheter Aortic Valve Replacement Implant Passes FDA's Muster, Shares Gain
Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ ...
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Johnson & Johnson reportedly in talks to acquire Shockwave Medical. Potential acquisition aligns with J&J's interest in ...
Medtronic PLC's Dividend Analysis
Medtronic PLC (NYSE:MDT) recently announced a dividend of $0.69 per share, payable on 2024-04-12, with the ex-dividend date ...
Medtronic receives top accolade in 3 countries at Healthcare Asia Medtech Awards 2024
SINGAPORE - Media OutReach Newswire - 27 March 2024 - Medtronic has grabbed major titles at the recent Healthcare Asia ...
Medtronic a Top Ranked SAFE Dividend Stock With 3.3% Yield (MDT)
Medtronic PLC (Symbol: MDT) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.3% yield ...
Investors in Medtronic (NYSE:MDT) have unfortunately lost 23% over the last three years
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your ...
FDA Approves Evolut TAVR System, Medtronic’s Treatment for Symptomatic Severe Aortic Stenosis
Evolut FX+ transcatheter aortic valve replacement system design includes a larger coronary access window through a modified ...
Medtronic secures FDA approval for evolved Evolut TAVR valve
The latest generation of Medtronic’s transcatheter aortic valve replacement implant has passed the FDA’s muster. | The main ...
Medtronic Plc
These dividend stocks should prosper regardless of what happens with interest rates in 2024.
Medtronic plc: Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis
The Evolut FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) ...
Loading the latest forecasts...